Search Results

Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.

Fosun Pharma USA Inc. (“Fosun Pharma USA”) is pleased to announce that Chief Executive Officer, Rong Yang, and several Fosun Pharma USA executives, will be attending the 42nd Annual J.P. Morgan Healthcare Conference (JPM ’24), taking place in San Francisco, California, Jan. 8 - 11, 2024.

Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC).

Natco Pharma Limited, a research and development -focused pharmaceutical company based in India, announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.

Poolbeg Pharma announces that, further to its announcement on20 March 2024,the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Coya Therapeutics, Inc. announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.

Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies.